Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein

Journal of Experimental Medicine

Volumn 191, Issue 11, 2000, Pages 1945-1956

  Siegel, Christopher T ^a   Schreiber, Karin ^a   Meredith, Stephen C ^a   Beck Engeser, Gabriele B ^a   Lancki, David W ^a   Lazarski, Christopher A ^a   Fu, Yang Xin ^a   Rowley, Donald A ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Active immunization; Immune stimulation; Mutant ras gene cancer prone mice; Primary tumor

Indexed keywords

ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE RAS; PAPILLOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, NEOPLASM; ARGININE; CANCER VACCINES; FEMALE; GLYCINE; MALE; MICE; MICE, INBRED C57BL; ONCOGENE PROTEIN P21(RAS); PAPILLOMA; PEPTIDES; POINT MUTATION; VACCINATION;

EID: 0034608365     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.11.1945     Document Type: Article

References (70)

1. Fearon, E.R. 1997. Human cancer syndromes: clues to the origin and nature of cancer. Science. 278:1043-1050.
2. Leder, A., A. Kuo, R.D. Cardiff, E. Sinn, and P. Leder. 1990. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA. 87:9178-9182.
3. Barbacid, M. 1987. ras genes. Annu. Rev. Biochem. 56:779-827.
4. Germolec, D.R., J. Spalding, H.S. Yu, G.S. Chen, P.P. Simeonova, M.C. Humble, A. Bruccoleri, G.A. Boorman, J.F. Foley, T. Yoshida, and M.I. Luster. 1998. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153:1775-1785.
5. Cannon, R.E., J.W. Spalding, C.S. Trempus, C.J. Szczesniak, K.M. Virgil, M.C. Humble, and R.W. Tennant. 1997. Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol. Carcinog. 20:108-114.
6. Hansen, L.A., and R. Tennant. 1994. Focal transgene expression associated with papilloma development in v-Ha-ras-transgenic TG.AC mice. Mol. Carcinog. 9:143-154.
7. Cannon, R.E., J.W. Spalding, K.M. Virgil, R.S. Faircloth, M.C. Humble, G.D. Lacks, and R.W. Tennant. 1998. Induction of transgene expression in Tg.AC(v-Ha-ras) transgenic mice concomitant with DNA hypomethylation. Mol. Carcinog. 21:244-250.
8. Peace, D.J., W. Chen, H. Nelson, and M.A. Cheever. 1991. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J. Immunol. 146:2059-2065.
9. Fujiwara, H., M. Fukuzawa, T. Yoshioka, H. Nakajima, and T. Hamaoka. 1984. The role of tumor-specific Lyt-1+2-T cells in eradicating tumor cells in vivo. I. Lyt-1+2-T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J. Immunol. 133:1671-1676.
10. - T cells. J. Exp. Med. 161:1122-1134.
11. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA. 96: 8633-8638.
12. Weaver, J.L., J.F. Contrera, B.A. Rosenzweig, K.L. Thompson, P.J. Faustino, J.M. Strong, C.D. Ellison, L.W. Anderson, H.R. Prasanna, P.E. Long-Bradley, et al. 1998. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol. Pathol. 26:532-540.
13. Thompson, K.L., B.A. Rosenzweig, and F.D. Sistare. 1998. An evaluation of the hemizygous transgenic TG.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol. Pathol. 26:548-555.
14. Ward, P.L., H. Koeppen, T. Hurteau, and H. Schreiber. 1989. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells J. Exp. Med. 1711:217-232.
15. Naito, M., K.J. Chenicek, Y. Naito, and J. DiGiovanni. 1988. Susceptibility to phorbol ester skin tumor promotion in (C57BL/6 × DBA/2) F1 mice is inherited as an incomplete dominant trait: evidence for multi-locus involvement. Carcinogenesis. 9:639-645.
16. Monach, P.A., S.C. Meredith, C.T. Siegel, and H. Schreiber. 1995. A unique tumor antigen produced by a single amino acid substitution. Immunity. 2:45-59.
17. Lacal, J.C., and S.A. Aaronson. 1986. ras p21 deletion mutants and monoclonal antibodies as tools for localization of regions relevant to p21 function. Proc. Natl. Acad. Sci. USA. 83: 5400-5404.
18. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:55-63.
19. Engvall, E., and P. Perlman. 1971. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry. 8:871-874.
20. Fenton, R.G., D.D. Taub, L.W. Kwak, M.R. Smith, and D.L. Longo. 1993. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras protooncogenes. J. Natl. Cancer Inst. 85:1294-1302.
21. Rous, P., and J.G. Kidd. 1941. Conditional neoplasms and subthreshold neoplastic states. A study of the tar tumors of rabbits. J. Exp. Med. 73:365-390.
22. MacKenzie, I., and P. Rous. 1941. The experimental disclosure of latent neoplastic changes in tarred skin. J. Exp. Med. 73:391-415.
23. Schreiber, H., and D.A. Rowley. 1999. Inflammation and cancer. In Inflammation: Basic Principles and Clinical Correlates. 3rd ed. J.I. Gallin and R. Snyderman, editors. Lippincott Williams and Wilkins, Philadelphia. 1117-1129.
24. Yuspa, S.H. 1994. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis - thirty-third G.H.A. Clowes Memorial Award Lecture. Cancer Res. 54:1178-1189.
25. Prehn, R.T. 1972. The immune reaction as a stimulator of tumor growth. Science. 176:170-171.
26. Prehn, R.T. 1994. Stimulatory effects of immune reactions upon the growths of untransplanted tumors. Cancer Res. 54: 908-914.
27. Nakamoto, Y., L.G. Guidotti, C.V. Kuhlen, P. Fowler, and F.V. Chisari. 1998. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188:341-350.
28. Esserman, L.J., T. Lopez, R. Montes, L.N. Bald, B.M. Fendly, and M.J. Campbell. 1999. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother. 47:337-342.
29. Snell, G.D. 1957. Incompatibility reactions to tumor homotransplants with particular reference to the role of the tumor. Cancer Res. 17:2-10.
30. Kaliss, N. 1957. Immunological enhancement of tumor homografts in mice. A review. Cancer Res. 18:992-1003.
31. Bubenik, J., and A. Turano. 1968. Enhancing effect on tumour growth of humoral antibodies against tumour specific transplantation antigens in tumours induced by murine sarcoma virus (Harvey). Nature: 220:928-930.
32. Monach, P.A., H. Schreiber, and D.A. Rowley. 1993. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation. 55:1356-1361.
33. Qin, Z., G. Richter, T. Schiller, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4:627-630.
34. Ibanez, O.M., D. Mouton, O.G. Ribeiro, Y. Bouthillier, M. De Franco, W.H. Cabrera, M. Siqueira, and G. Biozzi. 1999. Low antibody responsiveness is found to be associated with resistance to chemical skin tumorigenesis in several lines of Biozzi mice. Cancer Lett. 136:153-158.
35. Brodt, P., and J. Gordon. 1982. Natural resistance mechanisms may play a role in protection against chemical carcinogenesis. Cancer Immunol. Immunother. 13:125-127.
36. Manson, L.A. 1994. Anti-tumor immune responses of the tumor-bearing host: the case for antibody-mediated immunologic enhancement. Clin. Immunol. Immunopathol. 72:1-8.
37. Stach, R.M., and D.A. Rowley. 1993. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens. J. Exp. Med. 178:841-852.
38. Rowley, D.A., and R.M. Stach. 1998. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses. Int. Immunol. 10:355-363.
39. Speidel, K., W. Osen, S. Faath, I. Hilgert, R. Obst, J. Braspenning, F. Momburg, G.J. Hammerling, and H.G. Rammensee. 1997. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur. J. Immunol. 27:2391-2399.
40. Cardiff, R.D., A. Leder, A. Kuo, P.K. Pattengale, and P. Leder. 1993. Multiple tumor types appear in a transgenic mouse with the ras oncogene. Am. J. Pathol. 142:1199-1207.
41. Wijesuriya, R., S. Maruo, J.P. Zou, M. Ogawa, K. Umehara, M. Yamashita, S. Ono, H. Fujiwara, and T. Hamaoka. 1998. B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-hearing state. Int. Immunol. 10:1057-1065.
42. Kaplan, D.H., V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, L.J. Old, and R.D. Schreiber. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 95: 7556-7561.
43. Nozawa, H., E. Oda, K. Nakao, M. Ishihara, S. Ueda, T. Yokochi, K. Ogasawara, Y. Nakatsuru, S. Shimizu, Y. Ohira, et al. 1999. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev. 13:1240-1245.
44. Hruban, R.H., A.D. van Mansfeld, G.J. Offerhaus, D.H. van Weering, D.C. Allison, S.N. Goodman, T.W. Kensler, K.K. Bose, J.L. Cameron, and J.L. Bos. 1993. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-speciflc oligonucleotide hybridization. Am. J. Pathol. 143:545-554.
45. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725-729.
46. Fenton, R.G., C.J. Keller, N. Hanna, and D.D. Taub. 1995. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J. Natl. Cancer Inst. 87:1853-1861.
47. Carbone, G., M.G. Borrello, A. Molla, M.G. Rizzetti, M.A. Pierotti, G. Della Porta, and G. Parmiani. 1991. Activation of ras oncogenes and expression of tumor-specific transplantation antigens in methylcholanthrene-induced murine fibrosarcomas. Int. J. Cancer. 47:619-625.
48. + T lymphocytes following in vivo adoptive transfer. Cell. Immunol. 194:78-89.
49. Peace, D.J. J.W. Smith, W. Chen, S.G. You, W.L. Cosand, J. Blake, and M.A. Cheever. 1994. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J. Exp. Med. 179:473-479.
50. Bristol, J.A., J. Schlom, and S.I. Abrams. 1998. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties. J. Immunol. 160:2433-2441.
51. Toes, R.E., R. Offringa, R.J. Blom, C.J. Melief, and W.M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA. 93:7855-7860.
52. Van Elsas, A., H.W. Nijman, C.E. Van der Minne, J.S. Mourer, W.M. Kast, C.J. Melief, and P.I. Schrier. 1995. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int. J. Cancer. 61:389-396.
53. Abrams, S.I., S.N. Khleif, E.S. Bergmann-Leitner, J.A. Kantor, Y. Chung, J.M. Hamilton, and J. Schlom. 1997. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell. Immunol. 182:137-151.
54. Yokomizo, H., S. Matsushita, S. Fujisao, S. Murakami, H. Fujita, M. Shirouzu, S. Yokoyama, M. Ogawa, and Y. Nishimura. 1997. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides. Hum. Immunol. 52:22-32.
55. Ngo-Giang-Huong, N., M. Kayibanda, B. Deprez, J.P. Levy, J.G. Guillet, and A.F. Tilkin. 1995. Mutations in residue 61 of H-Ras p21 protein influence MHC class II presentation. Int. Immunol. 7:269-275.
56. Gedde-Dahl, T., III, A. Spurkland, B. Fossum, A. Wittinghofer, E. Thorsby, and G. Gaudernack. 1994. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Eur. J. Immunol. 24:410-414.
57. Peace, D.J., J.W. Smith, M.L. Disis, W. Chen, and M.A. Cheever. 1993. Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein. J. Immunother. 14:110-114.
58. Qin, H., W. Chen, M. Takahashi, M.L. Disis, D.R. Byrd, L. McCahill, K.A. Bertram, R.G. Fenton, D.J. Peace, and M.A. Cheever. 1995. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res. 55: 2984-2987.
59. Gjertsen, M.K., A. Bakka, J. Breivik, I. Saeterdal, T. Gedde-Dahl III, K.T. Stokke, B.G. Solheim, T.S. Egge, O. Soreide, E. Thorsby, and G. Gaudernack. 1996. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int. J. Cancer. 65:450-453.
60. Gedde-Dahl, T., III, J.A. Eriksen, E. Thorsby, and G. Gaudernack. 1992. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum. Immunol. 33:266-274.
61. Fossum, B., T. Gedde-Dahl III, T. Hansen, J.A. Eriksen, E. Thorsby, and G. Gaudernack. 1993. Overlapping epitopes encompassing a point mutation (12 Gly-> Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur. J. Immunol. 23:2687-2691.
62. Johansen, B.H., T. Gedde-Dahl III, L.M. Sollid, F. Vartdal, E. Thorsby, and G. Gaudernack. 1994. Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules [published erratum at 40:468]. Scand. J. Immunol. 39:607-612.
63. Fossum, B., J. Breivik, G.I. Meling, T. Gedde-Dahl III, T. Hansen, I. Knutsen, T.O. Rognum, E. Thorsby, and G. Gaudernack. 1994. A K-ras 13Gly-> Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int. J. Cancer. 58:506-511.
64. Gedde-Dahl, T., III, E. Nilsen, E. Thorsby, and G. Gaudermck. 1994. Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras. Cancer Immunol. Immunother. 38:127-134.
65. Jung, S., and H.J. Schluesener. 1991. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J. Exp. Med. 173:273-276.
66. Abrams, S.I., M.J. Dobrzanski, D.T. Wells, S.F. Stanziale, S. Zaremba, L. Masuelli, J.A. Kantor, J. Schlom, and L. Masuelle. 1995. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21 [published erratum at 25:3525]. Eur. J. Immunol. 25:2588-2597.
67. Viner, N.J., C.A. Nelson, and E.R. Unanue. 1995. Identification of a major I-Ek-restricted determinant of hen egg lysozyme: limitations of lymph node proliferation studies in defining immunodominance and crypticity. Proc. Natl. Acad. Sci. USA. 92:2214-2218.
68. Ye, X., J. McCarrick, L. Jewett, and B.B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA. 91:3916-3920.
69. Granziero, L., S. Krajewski, P. Farness, L. Yuan, M.K. Courtney, M.R. Jackson, P.A. Peterson, and A. Vitiello. 1999. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur. J. Immnol. 29:1127-1138.
70. Khleif, S.N., S.I. Abrams, J.M. Hamilton, E. Bergmann-Leitner, A. Chen, A. Bastian, S. Bernstein, Y. Chung, C.J. Allegra, and J. Schlom. 1999. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J. Immunother. 22:135-165.